-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
HCW Biologics Inc. (NASDAQ:HCWB) Sees Large Growth in Short Interest
HCW Biologics Inc. (NASDAQ:HCWB) Sees Large Growth in Short Interest
HCW Biologics Inc. (NASDAQ:HCWB – Get Rating) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 26,200 shares, an increase of 84.5% from the November 15th total of 14,200 shares. Based on an average daily trading volume, of 21,100 shares, the short-interest ratio is currently 1.2 days. Currently, 0.2% of the shares of the stock are sold short.
Wall Street Analyst Weigh In
Separately, Jonestrading began coverage on shares of HCW Biologics in a research note on Monday, November 7th. They issued a "buy" rating and a $8.00 price target on the stock.
Get HCW Biologics alerts:Institutional Investors Weigh In On HCW Biologics
Several hedge funds and other institutional investors have recently bought and sold shares of HCWB. HighTower Advisors LLC increased its position in HCW Biologics by 2,056.0% during the first quarter. HighTower Advisors LLC now owns 215,598 shares of the company's stock worth $588,000 after purchasing an additional 205,598 shares during the last quarter. BlackRock Inc. increased its position in HCW Biologics by 136.8% during the first quarter. BlackRock Inc. now owns 39,583 shares of the company's stock worth $108,000 after purchasing an additional 22,869 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in HCW Biologics by 9.8% during the third quarter. Vanguard Group Inc. now owns 95,392 shares of the company's stock worth $218,000 after purchasing an additional 8,494 shares during the last quarter. 1.59% of the stock is currently owned by institutional investors and hedge funds.
HCW Biologics Price Performance
HCW Biologics stock traded up $0.17 during midday trading on Thursday, hitting $2.10. 67,140 shares of the stock were exchanged, compared to its average volume of 33,825. HCW Biologics has a fifty-two week low of $1.76 and a fifty-two week high of $3.32. The stock's 50-day simple moving average is $2.18 and its 200 day simple moving average is $2.28. The company has a debt-to-equity ratio of 0.15, a current ratio of 12.52 and a quick ratio of 12.52.HCW Biologics Company Profile
(Get Rating)
HCW Biologics Inc, a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
See Also
- Get a free copy of the StockNews.com research report on HCW Biologics (HCWB)
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
HCW Biologics Inc. (NASDAQ:HCWB – Get Rating) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 26,200 shares, an increase of 84.5% from the November 15th total of 14,200 shares. Based on an average daily trading volume, of 21,100 shares, the short-interest ratio is currently 1.2 days. Currently, 0.2% of the shares of the stock are sold short.
新華生物股份有限公司(納斯達克代碼：HCWB-GET評級)是11月份空頭股數大幅增長的接受者。截至11月30日，空頭股數共有26,200股，比11月15日的14,200股增長了84.5%。以日均成交量2.11萬股計算，目前短息比為1.2天。目前，該股0.2%的股份被賣空。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Separately, Jonestrading began coverage on shares of HCW Biologics in a research note on Monday, November 7th. They issued a "buy" rating and a $8.00 price target on the stock.
另外，Jones Trading在11月7日星期一的一份研究報告中開始報道HCW Biologics的股票。他們對該股的評級為“買入”，目標價為8.00美元。
Institutional Investors Weigh In On HCW Biologics
機構投資者看好HCW生物製品
Several hedge funds and other institutional investors have recently bought and sold shares of HCWB. HighTower Advisors LLC increased its position in HCW Biologics by 2,056.0% during the first quarter. HighTower Advisors LLC now owns 215,598 shares of the company's stock worth $588,000 after purchasing an additional 205,598 shares during the last quarter. BlackRock Inc. increased its position in HCW Biologics by 136.8% during the first quarter. BlackRock Inc. now owns 39,583 shares of the company's stock worth $108,000 after purchasing an additional 22,869 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in HCW Biologics by 9.8% during the third quarter. Vanguard Group Inc. now owns 95,392 shares of the company's stock worth $218,000 after purchasing an additional 8,494 shares during the last quarter. 1.59% of the stock is currently owned by institutional investors and hedge funds.
幾家對沖基金和其他機構投資者最近買賣了華僑銀行的股票。HighTower Advisors LLC在第一季度將其在HCW Biologics的地位增加了2056.0%。HighTower Advisors LLC在上個季度額外購買了205,598股後，現在擁有215,598股該公司股票，價值58.8萬美元。貝萊德股份有限公司在第一季度增持了136.8%的惠康生物股份。貝萊德股份有限公司在上個季度增持了22,869股後，現在持有39,583股該公司股票，價值108,000美元。最後，先鋒集團在第三季度將其在HCW Biologics的頭寸增加了9.8%。先鋒集團(Vanguard Group Inc.)在上個季度增持了8,494股後，目前持有95,392股該公司股票，價值21.8萬美元。該股目前由機構投資者和對沖基金持有1.59%。
HCW Biologics Price Performance
HCW生物製品性價比
HCW Biologics Company Profile
HCW生物製品公司簡介
(Get Rating)
(獲取評級)
HCW Biologics Inc, a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
HCW生物製藥公司是一家臨床前階段的生物製藥公司，專注於發現和開發針對慢性、低級別炎症和年齡相關疾病的新型免疫療法。該公司的主導產品包括HCW9218，這是一種可注射免疫療法，用於治療胰腺癌、卵巢癌、乳腺癌、前列腺癌和結直腸癌以及肺纖維化患者；以及HCW9302，用於治療自身免疫性疾病，如斑禿和代謝性疾病。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on HCW Biologics (HCWB)
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 免費獲取StockNews.com關於HCW生物製品的研究報告(HCWB)
- 現在不是購買Lennar的時候，但時機即將到來
- 馬倫汽車公司改變遊戲規則的消息
- 通貨膨脹和能源危機是兩列相撞的貨運列車--以下是如何做好準備的
- 企業產品合作夥伴是否得到公平評價？
- WhatsApp合作夥伴關係是否會提振MercadoLibre的收益？
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《HCW生物製品日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對HCW Biologics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧